ARID1A and female reproductive organ cancer: In conclusion, this analysis confirms and strengthens existing literature (pretty high frequency of ARID1A alterations among solid tumors, especially particular subtypes of gynecological cancers, higher value of TMB, poorest outcomes among ARID1A+ cancers, no predictive role for platinum-based chemotherapy).